Gene therapy for ovarian cancer (review).
The field of gene therapy presents exciting new opportunities for advances in the management of ovarian cancer. Clinical trials of gene therapy for ovarian cancer have explored the feasibility of delivering a variety of agents as well as highlighted problems with the delivery of therapeutic constructs. Major challenges include enhancing gene transfection with improved vectors, minimizing immunogenicity of viral vectors via novel molecular alterations, effecting tumor-selective gene delivery by targeting genetic alterations present only in tumor cells and utilizing tissue-specific promoters for selective transcription of gene products. Gene therapy research presents unique opportunities for extending the spectrum of ovarian cancer treatment possibilities, either alone or in combination with conventional chemotherapy regimens.
Wolf
Judith K
JK
Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 440, Houston, TX 77030, USA. jwolf@mdanderson.org
Jenkins
A Dwayne
AD
D000260:Adenoviruses, Human / Q000235:genetics; D002986:Clinical Trials as Topic; D005260:Female; D005544:Forecasting; D015774:Ganciclovir / Q000494:pharmacology / Q000627:therapeutic use; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000628:therapy; D011401:Promoter Regions, Genetic; D012190:Retroviridae / Q000235:genetics; D018139:Simplexvirus / Q000235:genetics; D013937:Thymidine Kinase / Q000037:antagonists & inhibitors / Q000235:genetics
D013937:Thymidine Kinase; D015774:Ganciclovir